Acute myeloid leukemia (AML) is a malignant disease of myeloid hematopoietic stem or progenitor cells characterized by abnormal proliferation of primary and immature myeloid cells in bone marrow and peripheral blood. Gene mutation and expression profiles can be used as prognosis predictors for different prognostic subgroups. Secretory carrier-associated membrane proteins (SCAMPs) are a multigenic family with five members and act as cell surface vectors in the post-Golgi recycling pathways in mammals. Nevertheless, the prognostic and clinical influence of SCAMP family has hardly ever been illustrated in AML. In our study, expression patterns of SCAMP family (SCAMP1-5) were analyzed in 155 AML patients which were extracted from the Cancer Genome Atlas database. In chemotherapy, only subgroup, higher SCAMP1 level was significantly associated with longer EFS and OS (all P = 0.002), and SCAMP1 was confirmed to be an independent favorable factor in un-transplanted patients by Multivariate analysis (all P < 0.05). Nevertheless, in the allogeneic hematopoietic stem cell transplantation (allo-HSCT) treatment subgroup, none of the SCAMP genes had any effect on the clinical survival. Our study found that high expression level of SCAMP1 is a favorable prognostic factor in AML, but allo-HSCT may neutralize its prognostic effect.

中文翻译：

---

SCAMP家族在急性髓样白血病中的预后作用。

急性髓细胞性白血病（AML）是一种骨髓造血干细胞或祖细胞的恶性疾病，其特征是骨髓和外周血中原代和未成熟的髓样细胞异常增殖。基因突变和表达谱可以用作不同预后亚组的预后指标。分泌性载体相关膜蛋白（SCAMP）是具有五个成员的多基因家族，在哺乳动物的高尔基后循环途径中充当细胞表面载体。尽管如此，在AML中几乎没有说明SCAMP家族的预后和临床影响。在我们的研究中，分析了从癌症基因组图谱数据库中提取的155名AML患者的SCAMP家族（SCAMP1-5）的表达模式。在化学疗法中，只有亚组，较高的SCAMP1水平与更长的EFS和OS显着相关（所有P = 0.002），并且通过多变量分析证实SCAMP1是未移植患者的独立有利因素（所有P <0.05）。然而，在同种异体造血干细胞移植（allo-HSCT）治疗亚组中，没有一种SCAMP基因对临床存活率有任何影响。我们的研究发现SCAMP1的高表达水平是AML的有利预后因素，但allo-HSCT可能会中和其预后效果。SCAMP基因均未对临床生存产生任何影响。我们的研究发现SCAMP1的高表达水平是AML的有利预后因素，但allo-HSCT可能会中和其预后效果。SCAMP基因均未对临床生存产生任何影响。我们的研究发现SCAMP1的高表达水平是AML的有利预后因素，但allo-HSCT可能会中和其预后效果。